Ibrutinib Proves Formidable Treatment for CLL or SLL Patients

IbrutinibPatients suffering from chronic lymphocytic leukemia {CLL} or small lymphocytic lymphoma {SLL} can breathe easier with the latest findings regarding Ibrutinib. Study results revealed at the beginning of June 2014 showed that the powerful anti-cancer drug Ibrutinib elicited a significant improvement for patients with either chronic lymphocytic leukemia or small lymphocytic lymphoma in both overall survival and progression free survival in a study comparing it with Ofatumumab. The overall response rate was also notable in study participants, who were treated with one of the two best in care drugs, Ibrutinib or Ofatumumab. Ibrutinib is also known as the brand name Imbruvica, which is marketed by Janssen /Pharmacyclics and Ofatumumab is known as the brand name Arzerra, which is marketed by GlaxoSmithKline. These two viable medications proved to be unequal in comparison, however, despite R&D predictions. Ibrutinib bested Ofatumumab when administered to patients who had acute chronic lymphocytic leukemia or small lymphocytic lymphoma. The patients in this Phase III trial, coined RESONATE, had previously received treatment for their conditions, which were deemed unresectable. The surprise came when data gleaned showed that the participants who were given Ibrutinib displayed a 78 percent reduction in their risk of death and cancer progression as compared to the patients who were dosed with Ofatumumab.

Ibrutinib has succeeded in making quite an impression in the pharmaceutical arena over the past few years, receiving three FDA breakthrough designations and being touted as a safe and tolerable anti-cancer treatment. The FDA has officially approved the use of Ibrutinib for patients with chronic lymphocytic leukemia and mantle cell lymphoma, who have received at least one prior treatment. Ibrutinib is administered as an easy to swallow capsule to be taken once a day at approximately the same time each day, with a full glass of water.

LGM Pharma is a provider of the APIs Ibrutinib, CAS # 936563-96-1 and Ofatumumab, CAS # 679818-59-8 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: